Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Cash from Financing Activities (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Cash from Financing Activities for 6 consecutive years, with $934000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities rose 16.75% to $934000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $220.6 million, a 18.33% decrease, with the full-year FY2025 number at $1.6 million, down 99.41% from a year prior.
  • Cash from Financing Activities was $934000.0 for Q4 2025 at Relay Therapeutics, up from $17000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $384.0 million in Q4 2021 to a low of $17000.0 in Q3 2025.
  • A 5-year average of $54.7 million and a median of $1.8 million in 2022 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: skyrocketed 685635.71% in 2021, then plummeted 99.99% in 2025.
  • Relay Therapeutics' Cash from Financing Activities stood at $384.0 million in 2021, then plummeted by 99.7% to $1.2 million in 2022, then skyrocketed by 1779.76% to $21.9 million in 2023, then tumbled by 96.35% to $800000.0 in 2024, then grew by 16.75% to $934000.0 in 2025.
  • Per Business Quant, the three most recent readings for RLAY's Cash from Financing Activities are $934000.0 (Q4 2025), $17000.0 (Q3 2025), and $800000.0 (Q4 2024).